Domperidone + CinnarizineThird Party Manufacturing in India

Domperidone + Cinnarizine combines two mechanistically distinct antiemetic agents that work synergistically to control nausea, vomiting, and vertigo. Domperidone is a peripheral dopamine D2 receptor antagonist that acts on the chemoreceptor trigger zone and gastrointestinal tract. By blocking dopamine receptors, it enhances gastric motility, increases lower esophageal sphincter pressure, and facilitates gastric emptying. Its limited penetration across the blood-brain barrier reduces the risk of central extrapyramidal side effects while maintaining effective peripheral antiemetic activity.

Cinnarizine is a piperazine derivative with multiple pharmacological actions. It blocks L-type and T-type voltage-gated calcium channels in vascular smooth muscle, producing cerebral vasorelaxation and improving labyrinthine blood flow. Cinnarizine also antagonizes histamine H1 receptors, which contributes to its antivertigo and antihistaminic effects. In the vestibular system, it inhibits calcium translocation across sensory cells in the ampullae and maintains endolymph flow by preventing constriction of the stria vascularis. Additionally, cinnarizine binds to dopamine D2 receptors and muscarinic receptors, further contributing to its antiemetic profile.

The combination is particularly effective because domperidone addresses the gastrointestinal prokinetic component while cinnarizine targets the vestibular and central mechanisms of vertigo and motion sickness, providing comprehensive symptom control.

Therapeutic Uses

Domperidone + Cinnarizine is prescribed for the treatment of:

• Motion Sickness: The combination is highly effective for prevention and treatment of nausea, vomiting, and dizziness associated with travel by road, air, or sea.
• Vestibular Disorders: Including Meniere's disease and other inner ear conditions presenting with vertigo, tinnitus, nausea, and vomiting.
• Vertigo of Central and Peripheral Origin: Both acute and chronic vertigo episodes where the antivertigo action of cinnarizine complements the antiemetic effect of domperidone.
• Nausea and Vomiting Associated with Migraine: Where vestibular symptoms accompany headache episodes.

Why Manufacturers Choose Domperidone + Cinnarizine

This combination is well-established in markets across Asia, Africa, and the Middle East for the management of motion sickness and vertigo. The synergistic mechanism allows for lower individual doses while maintaining efficacy. Both domperidone and cinnarizine are commercially available APIs with established supply chains in India.

Formulation into tablet dosage form is straightforward using standard pharmaceutical manufacturing processes. The combination enjoys particular popularity in the Indian subcontinent, Middle East, and African markets where vertigo and motion sickness are common presenting complaints. This makes Domperidone + Cinnarizine a reliable product for third party manufacturing in India, with steady demand from PCD franchise networks and export-oriented pharmaceutical companies.